PYC achieves key designation for drug aiming to treat blinding eye disease ADOA
PYC Therapeutics Ltd has received a special designation from the FDA for its drug PYC-001 to treat a childhood-originating eye disease.
BPL
0.00%
11.4¢
![](/images/icons/chart-icon.png)
Broken Hill Prospecting Limited - Corporate Spotlight
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.